Table 3. Cycle 1 Adverse Event Summary (n=31).

	Total n (%)	Grade 3 n (%)	Grade 4 n (%)
Haematologic
Leukocytopenia	20 (54%)	4 (11%)	4 (11%)
Neutropenia	2 (6%)	0	2 (6%)
Anaemia	15 (40%)	2 (6%)	1 (3%)
Thrombocytopenia	21 (58%)	6 (17%)	5 (14%)
Non-haematologic
Hypoalbuminemia	20 (54%)	0	0
Elevated alkaline phosphatase	17 (46%)	9 (24%)	0
Elevated ALT	13 (35%)	0	0
Anorexia	20 (54%)	1 (3%)	0
Elevated AST	19 (51%)	0	0
Hyperbilirubinemia	9 (24%)	1 (3%)	0
Hypocalcemia	25 (68%)	0	0
Constipation	12 (32%)	0	0
Diarrhoea	15 (40%)	1 (3%)	0
Dysgeusia	7 (19%)	0	0
Dyspnoea	10 (27%)	0	0
Oedema	6 (17%)	0	0
Fatigue	16 (43%)	0	0
Hypertension	8 (22%)	1 (3%)	0
Mucositis	6 (17%)	0	0
Nausea	10 (27%)	1 (3%)	0
Peripheral neuropathy	10 (28%)	0	0
Pain	30 (81%)	2 (6%)	0
Hypokalemia	9 (24%)	0	1 (3%)
Hyponatremia	20 (56%)	0	0
Vomiting	7 (19%)	1 (3%)	0